- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe atopic dermatitis
- Meeting Date: July 2021
- Public Summary Document (PSD) July 2021 PBAC Meeting - (PDF 1372KB)
- Public Summary Document (PSD) July 2021 PBAC Meeting - (Word 127KB)
Baricitinib – July 2021
Baricitinib: Tablet 2 mg, Tablet 4 mg; Olumiant®
Last updated
12 November 2021